LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company,
announced that Alan H. Auerbach, Chairman, Chief Executive Officer,
President and Founder of Puma, will provide an overview of the Company
at 11:20 a.m. EDT on Tuesday, March 13, at the Cowen and Company 38th
Annual Health Care Conference. The conference will be held at the Boston
Marriott Copley Place.
A live webcast of the presentation will be available on the Company’s
website at
www.pumabiotechnology.com
.
The presentation will be archived on the website and available for 30
days.
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on
the development and commercialization of innovative products to enhance
cancer care. The Company in-licenses the global development and
commercialization rights to three drug candidates — PB272 (neratinib,
oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was
approved by the U.S. Food and Drug Administration in July 2017 for the
extended adjuvant treatment of adult patients with early stage
HER2-overexpressed/amplified breast cancer, following adjuvant
trastuzumab-based therapy, and is marketed in the United States as
NERLYNX® (neratinib) tablets. NERLYNX is a registered trademark of Puma
Biotechnology, Inc.
Further information about Puma Biotechnology can be found at www.pumabiotechnology.com.
Forward-Looking Statements
This press release and the webcast of the presentation contain
forward-looking statements, including statements regarding the benefits
of NERLYNX® and neratinib, the Company’s clinical trials and the
announcement of data relative to those trials. All forward-looking
statements involve risks and uncertainties that could cause the
Company’s actual results to differ materially from the anticipated
results and expectations expressed in these forward-looking statements.
These statements are based on current expectations, forecasts and
assumptions, and actual outcomes and results could differ materially
from these statements due to a number of factors, which include, but are
not limited to, the risk factors disclosed in the periodic reports filed
by the Company with the Securities and Exchange Commission from time to
time, including the Company’s Quarterly Report on Form 10-Q for the
quarter ended September 30, 2017. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak only as
of the date hereof. The Company assumes no obligation to update these
forward-looking statements, except as required by law.
Contact: